國藥股份(600511.SH)上半年淨利潤升18.66%至7.55億元
格隆匯8月21日丨國藥股份(600511.SH)發佈2019年半年度報告,實現營業收入210.22億元,同比增長11.99%;歸屬於上市公司股東的淨利潤7.55億元,同比增長18.66%;歸屬於上市公司股東的扣除非經常性損益的淨利潤7.28億元,同比增長14.64%;基本每股收益0.9872元。
2019年上半年,公司業務依然以醫藥流通為主,藥品分銷佔90%以上份額,且在北京地區醫藥商業保持龍頭地位。隨着醫藥改革逐步深入,公司北京地區直銷業務得到進一步拓展和提升,地區佔有率穩中有增,規模優勢明顯。全國分銷業務網絡覆蓋31個省市,受到兩票制政策影響,區域分銷業務縮小,外埠分銷業務在進口分銷業務帶動下保持較好的持續發展態勢;零售業務穩定增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.